Reimbursement Review Reports

The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.

Brand Name Sort descending Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued
Entyvio vedolizumab Crohn’s disease Reimburse with clinical criteria and/or conditions Complete
Entyvio Vedolizumab Ulcerative colitis List with clinical criteria and/or conditions Complete
Entyvio Vedolizumab Crohn's disease Reimburse with clinical criteria and/or conditions Complete
Entyvio vedolizumab Ulcerative Colitis Reimburse with clinical criteria and/or conditions Complete
Epclusa sofosbuvir / velpatasvir Hepatitis C, chronic Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. Not filed
Epclusa Sofosbuvir/ velpatasvir Hepatitis C, chronic Reimburse with clinical criteria and/or conditions Complete
Epidiolex cannabidiol Lennox-Gastaut Syndrome (LGS) Reimburse with clinical criteria and/or conditions Complete
Epidiolex cannabidiol Dravet Syndrome (DS) Reimburse with clinical criteria and/or conditions Complete
Epidiolex cannabidiol Seizures associated with Tuberous Sclerosis Complex (TSC) Reimburse with clinical criteria and/or conditions Complete
Epkinly epcoritamab Relapsed or refractory diffuse large B-cell lymphoma Time-limited reimbursement recommendation Active